Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment
Abstract The past decade has witnessed ongoing progress in immune therapy to ameliorate human health. As an emerging technique, chimeric antigen receptor (CAR) T-cell therapy has the advantages of specific killing of cancer cells, a high remission rate of cancer-induced symptoms, rapid tumor eradica...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-01-01
|
| Series: | Experimental Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40164-023-00373-7 |
| _version_ | 1811175972138909696 |
|---|---|
| author | Ting Yan Lingfeng Zhu Jin Chen |
| author_facet | Ting Yan Lingfeng Zhu Jin Chen |
| author_sort | Ting Yan |
| collection | DOAJ |
| description | Abstract The past decade has witnessed ongoing progress in immune therapy to ameliorate human health. As an emerging technique, chimeric antigen receptor (CAR) T-cell therapy has the advantages of specific killing of cancer cells, a high remission rate of cancer-induced symptoms, rapid tumor eradication, and long-lasting tumor immunity, opening a new window for tumor treatment. However, challenges remain in CAR T-cell therapy for solid tumors due to target diversity, tumor heterogeneity, and the complex microenvironment. In this review, we have outlined the development of the CAR T-cell technique, summarized the current advances in tumor-associated antigens (TAAs), and highlighted the importance of tumor-specific antigens (TSAs) or neoantigens for solid tumors. We also addressed the challenge of the TAA binding domain in CARs to overcome off-tumor toxicity. Moreover, we illustrated the dominant tumor microenvironment (TME)-induced challenges and new strategies based on TME-associated antigens (TMAs) for solid tumor CAR T-cell therapy. |
| first_indexed | 2024-04-10T19:45:35Z |
| format | Article |
| id | doaj.art-b8204c76fa554bb2a5d495b36830bf27 |
| institution | Directory Open Access Journal |
| issn | 2162-3619 |
| language | English |
| last_indexed | 2024-04-10T19:45:35Z |
| publishDate | 2023-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Experimental Hematology & Oncology |
| spelling | doaj.art-b8204c76fa554bb2a5d495b36830bf272023-01-29T12:06:13ZengBMCExperimental Hematology & Oncology2162-36192023-01-0112111810.1186/s40164-023-00373-7Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironmentTing Yan0Lingfeng Zhu1Jin Chen2Institute of Clinical Medicine, The Second Affiliated Hospital of Hainan Medical UniversityDepartment of Urology, The Second Affiliated Hospital of Hainan Medical UniversityInstitute of Clinical Medicine, The Second Affiliated Hospital of Hainan Medical UniversityAbstract The past decade has witnessed ongoing progress in immune therapy to ameliorate human health. As an emerging technique, chimeric antigen receptor (CAR) T-cell therapy has the advantages of specific killing of cancer cells, a high remission rate of cancer-induced symptoms, rapid tumor eradication, and long-lasting tumor immunity, opening a new window for tumor treatment. However, challenges remain in CAR T-cell therapy for solid tumors due to target diversity, tumor heterogeneity, and the complex microenvironment. In this review, we have outlined the development of the CAR T-cell technique, summarized the current advances in tumor-associated antigens (TAAs), and highlighted the importance of tumor-specific antigens (TSAs) or neoantigens for solid tumors. We also addressed the challenge of the TAA binding domain in CARs to overcome off-tumor toxicity. Moreover, we illustrated the dominant tumor microenvironment (TME)-induced challenges and new strategies based on TME-associated antigens (TMAs) for solid tumor CAR T-cell therapy.https://doi.org/10.1186/s40164-023-00373-7CAR T cellsSolid tumorTAAsTSAsTMAs |
| spellingShingle | Ting Yan Lingfeng Zhu Jin Chen Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment Experimental Hematology & Oncology CAR T cells Solid tumor TAAs TSAs TMAs |
| title | Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment |
| title_full | Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment |
| title_fullStr | Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment |
| title_full_unstemmed | Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment |
| title_short | Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment |
| title_sort | current advances and challenges in car t cell therapy for solid tumors tumor associated antigens and the tumor microenvironment |
| topic | CAR T cells Solid tumor TAAs TSAs TMAs |
| url | https://doi.org/10.1186/s40164-023-00373-7 |
| work_keys_str_mv | AT tingyan currentadvancesandchallengesincartcelltherapyforsolidtumorstumorassociatedantigensandthetumormicroenvironment AT lingfengzhu currentadvancesandchallengesincartcelltherapyforsolidtumorstumorassociatedantigensandthetumormicroenvironment AT jinchen currentadvancesandchallengesincartcelltherapyforsolidtumorstumorassociatedantigensandthetumormicroenvironment |